Your trusted source for pharmaceutical industry knowledge, regulatory insights, clinical research updates, and healthcare innovation.
Ionis Pharmaceuticals announced positive topline results from its pivotal Phase 1-3 study of zilganersen for Alexander disease (AxD), a rare and often fatal neurological condition.
Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase. The company announced a 3.
BeOne Medicines Ltd. (BGNE) filed an 8-K on April 14, 2026, pertaining to its 2025 Annual Report filed with the Shanghai Stock Exchange's STAR Market.
Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase.
AbbVie announced an update to its 2026 earnings guidance in an 8-K filing on April 3, 2026. The update reflects a $744 million pre-tax charge for acquired IPR&D (In-Process Research and Development) a...
Biogen Inc. announced it has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash, plus one contingent value right (CVR) potentially worth up to $4...
Incyte Corporation announced executive leadership title changes effective March 25, 2026. Pablo J. Cagnoni is now President, Incyte and Global Head of Research and Development, replacing William J.
Halozyme Therapeutics announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026.
Exelixis, Inc. filed an 8-K on March 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The press release, furnished as Exhibit 99.
Ionis Pharmaceuticals announced significant changes to its Board of Directors. B. Lynne Parshall and Joseph H. Wender will retire at the end of their terms in June 2026.